Activation of AT2 receptors prevents diabetic complications in female db/db mice by NO‐mediated mechanisms
- 26 August 2020
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (20) , 4766-4781
Abstract
Background and Purpose: The AT2 receptor plays a role in metabolism by opposing the actions triggered by the AT1 receptors. Activation of AT2 receptors has been shown to enhance insulin sensitivity in both normal and insulin resistance animal models. In this study, we investigated the mechanism by which AT2 receptors activation improves metabolism in diabetic mice.Experimental Approach: Female diabetic (db/db) and non‐diabetic (db/+) mice were treated for 1 month with the selective AT2 agonist, compound 21 (C21, 0.3 mg·kg−1·day−1, s.c.). To evaluate whether the effects of C21 depend on NO production, a subgroup of mice was treated with C21 plus a sub‐pressor dose of the NOS inhibitor l‐NAME (0.1 mg·ml−1, drinking water).Key Results: C21‐treated db/db mice displayed improved glucose and pyruvate tolerance compared with saline‐treated db/db mice. Also, C21‐treated db/db mice showed reduced liver weight and decreased hepatic lipid accumulation compared with saline‐treated db/db mice. Insulin signalling analysis showed increased phosphorylation of the insulin receptor, Akt and FOXO1 in the livers of C21‐treated db/db mice compared with saline‐treated counterparts. These findings were associated with increased adiponectin levels in plasma and adipose tissue and reduced adipocyte size in inguinal fat. The beneficial effects of AT2 receptors activation were associated with increased eNOS phosphorylation and higher levels of NO metabolites and were abolished by l‐NAME.Conclusion and Implications: Chronic C21 infusion exerts beneficial metabolic effects in female diabetic db/db mice, alleviating type 2 diabetes complications, through a mechanism that involves NO production.Keywords
Funding Information
- Universidad de Buenos Aires (UBACYT 20020130100218BA)
- Fondo para la Investigación Científica y Tecnológica (PICT‐2014‐0362)
- American Heart Association (17GRNT33661206, 16SDG30130015)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK007770, P30DK063491)
- National Heart, Lung, and Blood Institute (P01HL129941, R01HL142672)
This publication has 53 references indexed in Scilit:
- Vascular angiotensin II type 2 receptor attenuates atherosclerosis via a kinin/NO-dependent mechanismJournal of the Renin-Angiotensin-Aldosterone System, 2013
- Direct Angiotensin II Type 2 Receptor Stimulation Ameliorates Insulin Resistance in Type 2 Diabetes Mice with PPARγ ActivationPLOS ONE, 2012
- Sex-Specific Influence of Angiotensin Type 2 Receptor Stimulation on Renal FunctionHypertension, 2012
- Liver fibrosis: a balance of ACEs?Clinical Science, 2007
- Mechanisms linking obesity to insulin resistance and type 2 diabetesNature, 2006
- Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosisBiochemical and Biophysical Research Communications, 2006
- Inflammation and insulin resistanceJournal of Clinical Investigation, 2006
- Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Angiotensin II Type-1 Receptor Blocker Valsartan Enhances Insulin Sensitivity in Skeletal Muscles of Diabetic MiceHypertension, 2004
- Disruption of Adiponectin Causes Insulin Resistance and Neointimal FormationJournal of Biological Chemistry, 2002